Biocytogen Pharmaceuticals Beijing (2315) H1 2026 earnings summary

Executive summary

• H1 2026 revenue rose 51.6% YoY to RMB941.4m; net profit increased 402.3% to RMB241.1m, with operating cash inflow of RMB261.6m.

• Growth was driven by pre-clinical products and services and antibody discovery, supported by strong demand for innovative animal models and expanding global collaborations.

Financial highlights

• Revenue was RMB941.4m, up 51.6% YoY; gross profit increased 61.6% to RMB746.5m.

• Operating income was RMB305.1m versus RMB107.4m; profit before tax was RMB248.6m versus RMB59.6m, and net income was RMB241.1m versus RMB48.0m.

• Basic and diluted EPS was RMB0.54 versus RMB0.12; operating cash flow was RMB261.6m versus RMB203.4m.

• R&D expense increased 27.8% YoY to RMB267.3m; selling and marketing expense rose 30.3% to RMB76.2m, while G&A rose 14.5% to RMB133.0m.

Outlook and guidance

• Haimen animal-center facilities are scheduled to open before year-end, adding over 100,000 cages; a new Haimen production base is planned to support supply for the next 2–3 years.

• New pharmacology and efficacy service facilities are planned in Beijing Daxing and Boston; continued investment in pre-clinical R&D, capacity and overseas infrastructure is intended to support growth.

• Plans include expanding the antibody sequence library and licensing RenSuper Workstation, with AI and automation aimed at scaling discovery and increasing future upfront, milestone and royalty potential.